Long-acting GH analogs and GH fragments
Muscle & Strength · Growth hormone analog / fragment
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades Long-acting GH analogs and GH fragments as D (3.3/10) based on weak evidence, low-med benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: growth hormone/GH, lonapegsomatropin, somapacitan, somatrogon, AOD-9604 and hGH 176-191.
Studied, labeled, or reported-use context: Clinical GH-deficiency dosing is individualized; no safe anti-aging or performance dose — Rx for approved GH-deficiency indications or research chemical; WADA S2 prohibited; not individualized guidance.
What the evidence says
WADA coverage: growth hormone/GH, lonapegsomatropin, somapacitan, somatrogon, AOD-9604 and hGH 176-191. The existing HGH page covers recombinant GH; this row captures long-acting analogs and fragments.
Mechanism
Long-acting somatropin analogs replace GH in deficiency states; GH fragments are marketed for fat loss despite much weaker clinical evidence. Performance/anti-aging use extrapolates from GH biology.
Studied, labeled, or reported dose & route
Clinical GH-deficiency dosing is individualized; no safe anti-aging or performance dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Long-acting GH analogs and GH fragments's effects?
- Read Off Label rates the evidence for Long-acting GH analogs and GH fragments as Weak and the benefit magnitude as low-med, producing an overall grade of D (3.3/10). WADA coverage: growth hormone/GH, lonapegsomatropin, somapacitan, somatrogon, AOD-9604 and hGH 176-191.
- What safety findings are reported for Long-acting GH analogs and GH fragments?
- Long-acting GH analogs and GH fragments has a med-high risk profile in the database. Med-High (edema, insulin resistance, arthralgia, IGF-1 elevation for GH analogs; unknown risks for fragments) Legal status: Rx for approved GH-deficiency indications or research chemical; WADA S2 prohibited.
- What does the low Safety score for Long-acting GH analogs and GH fragments represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Long-acting GH analogs and GH fragments?
- Clinical GH-deficiency dosing is individualized; no safe anti-aging or performance dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Long-acting GH analogs and GH fragments work?
- Long-acting somatropin analogs replace GH in deficiency states; GH fragments are marketed for fat loss despite much weaker clinical evidence. Performance/anti-aging use extrapolates from GH biology.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.